1. Home
  2. LUCD vs SPRO Comparison

LUCD vs SPRO Comparison

Compare LUCD & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lucid Diagnostics Inc.

LUCD

Lucid Diagnostics Inc.

HOLD

Current Price

$0.99

Market Cap

182.2M

Sector

Health Care

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.13

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LUCD
SPRO
Founded
2018
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
182.2M
156.3M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
LUCD
SPRO
Price
$0.99
$2.13
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$4.13
N/A
AVG Volume (30 Days)
929.3K
837.3K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
16.67
111.81
EPS
N/A
N/A
Revenue
$4,346,000.00
$66,802,000.00
Revenue This Year
$115.58
N/A
Revenue Next Year
$130.54
$300.00
P/E Ratio
N/A
N/A
Revenue Growth
79.00
39.24
52 Week Low
$0.90
$1.80
52 Week High
$1.63
$3.09

Technical Indicators

Market Signals
Indicator
LUCD
SPRO
Relative Strength Index (RSI) 45.45 33.06
Support Level $0.90 $1.84
Resistance Level $1.12 $2.44
Average True Range (ATR) 0.05 0.25
MACD 0.01 -0.05
Stochastic Oscillator 33.08 14.77

Price Performance

Historical Comparison
LUCD
SPRO

About LUCD Lucid Diagnostics Inc.

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: